Bridge Biotherapeutics Inc
KOSDAQ:288330
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bridge Biotherapeutics Inc
KOSDAQ:288330
|
KR |
|
Silence Therapeutics PLC
OTC:SLNCF
|
UK |
|
Oaktree Specialty Lending Corp
F:FFC0
|
US |
Intrinsic Value
The intrinsic value of Bridge Biotherapeutics Inc (288330) under the Base Case is 372.24 KRW per share. Compared with the current market price of 416 KRW, the stock appears Overvalued by 11% .
The intrinsic value is calculated using the DCF method. The model assumes revenue returns to growth: about 131% a year over the next five years, after falling about 73% a year over the last five years. If revenue grew at its five-year pace of -73%, the estimate would be about ₩84. The forecast years subtract value, so the estimate rests entirely on the years after 2031.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Bridge Biotherapeutics Does
Bridge Biotherapeutics is a South Korean drug developer that creates experimental medicines, rather than selling finished pharmaceuticals. Its work centers on discovering and testing new treatments for diseases such as cancer, fibrotic lung disease, and inflammatory conditions. The company’s main job is to move drug candidates through lab work and clinical trials until they can be licensed or approved for sale.
- Headquarters
- Korea KR
- IPO date
- Dec 20, 2019
Revenue & Expenses Breakdown
Bridge Biotherapeutics Inc
Earnings Waterfall
Bridge Biotherapeutics Inc
The intrinsic value for Bridge Biotherapeutics Inc (288330) under the Base Case is 372.24 KRW.
Compared with the current market price of 416 KRW, the stock appears Overvalued by 11% .